Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.

A series of derivatives of the known thromboxane A2 prostanoid (TP) receptor antagonists, 3-(6-((4-chlorophenyl)sulfonamido)-5,6,7,8-tetrahydronaphthalen-1-yl)propanoic acid and 3-(3-(2-((4-chlorophenyl)sulfonamido)ethyl)phenyl) propanoic acid, were synthesized in which the carboxylic acid functional group was replaced with substituted cyclopentane-1,3-dione (CPD) bioisosteres. Characterization of these molecules led to the discovery of remarkably potent new analogues, some of which were considerably more active than the corresponding parent carboxylic acid compounds. Depending on the choice of the C2 substituent of the CPD unit, these new derivatives can produce either a reversible or an apparent irreversible inhibition of the human TP receptor. Given the potency and the long-lasting inhibition of TP receptor signaling, these novel antagonists may comprise promising leads for the development of antithromboxane therapies.

[1]  D. Dougherty.  The cation-π interaction. , 2013, Accounts of chemical research.

[2]  Harold J. Ting,et al.  Thromboxane A2 Receptor , 2012, Journal of cardiovascular pharmacology and therapeutics.

[3]  J. Trojanowski,et al.  Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease. , 2012, ACS chemical neuroscience.

[4]  K. Honn,et al.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis , 2011, Cancer and Metastasis Reviews.

[5]  J. Trojanowski,et al.  Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists. , 2011, Journal of medicinal chemistry.

[6]  B. Ovbiagele,et al.  Vascular events after stroke: terutroban fails to PERFORM , 2011, The Lancet.

[7]  E. Smyth.  Thromboxane and the thromboxane receptor in cardiovascular disease , 2010, Clinical lipidology.

[8]  Á. Chamorro,et al.  The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline Characteristics of the Population , 2009, Cerebrovascular Diseases.

[9]  Andrew G. Leach,et al.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.

[10]  Bin Zhang,et al.  Thromboxane Receptor Activation Mediates Isoprostane-Induced Increases in Amyloid Pathology in Tg2576 Mice , 2008, The Journal of Neuroscience.

[11]  N. Nakahata.  Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. , 2008, Pharmacology & therapeutics.

[12]  G. Trainor,et al.  The importance of plasma protein binding in drug discovery , 2007, Expert opinion on drug discovery.

[13]  Bernard Pirotte,et al.  From the design to the clinical application of thromboxane modulators. , 2006, Current pharmaceutical design.

[14]  L. Sorbera,et al.  Terutroban sodium. Prostanoid TP receptor antagonist. Antithrombotic agent. Antiatherosclerocic agent , 2006 .

[15]  G. Lavielle,et al.  New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[16]  G. Lavielle,et al.  Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. , 1998, Bioorganic & medicinal chemistry letters.

[17]  J. Steele,et al.  Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists. , 1997, Journal of medicinal chemistry.

[18]  D. A. Dougherty,et al.  The Cationminus signpi Interaction. , 1997, Chemical reviews.

[19]  P. H. van der Graaf,et al.  Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery. , 1996, European journal of pharmacology.

[20]  D. A. Dougherty,et al.  Cation-π Interactions in Chemistry and Biology: A New View of Benzene, Phe, Tyr, and Trp , 1996, Science.

[21]  Y. Yamamoto,et al.  Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction. , 1993, Journal of medicinal chemistry.

[22]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Hiraga.  Structures of cyclopentanepolyones. , 1965, Chemical & pharmaceutical bulletin.